

# GLOBAL MARKETS FOR GENERIC DRUGS



PHM009G  
January 2014

Paul Evers  
*Project Analyst*

ISBN: 1-56965-683-5

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

## TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
MARKET ANALYSES AND FORECASTS	3
METHODOLOGY	3
INTENDED AUDIENCE	3
INFORMATION SOURCES	3
ANALYST CREDENTIALS	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
MARKET SIZE AND EVOLUTION	7
<i>SUMMARY TABLE MAJOR NATIONAL GENERIC MARKETS, THROUGH 2018 (\$ BILLIONS)</i>	8
<i>SUMMARY FIGURE MAJOR NATIONAL GENERIC MARKETS, 2012-2018 (\$ BILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
<i>TABLE 1 GLOBAL PHARMACEUTICAL AND GENERICS MARKETS BY REGION, THROUGH 2018 (\$ BILLIONS)</i>	11
RECENT HISTORY OF THE GENERICS SECTOR	12
ROCHE-BOLAR	13
GENERICS LOBBY	13
ICH	14
CHAPTER 4 THE NEW GENERICS ERA	17
THE PATENT CLIFF	17
<i>TABLE 2 MAJOR PATENT EXPIRATIONS IN 2011 AND 2012</i>	18
<i>TABLE 3 MAJOR PATENT EXPIRIES IN 2013 WITH PEAK BRAND SALES BEFORE EXPIRIES</i>	18
<i>TABLE 4 BRAND SALES BEFORE AND AFTER PATENT EXPIRY (\$ BILLIONS)</i>	19
TYPES OF GENERICS	20
'SIMPLE' GENERICS	20
Adequate Market Size	20
Patent-expired Therapies	20
Older Products Still Used	21
Long-term Use	21
Straightforward Production Technology	21
Drugs Used in Primary Care	22
SUPERGENERICS	22
BIOSIMILARS	23
<i>TABLE 5 BIOTHERAPEUTICS AMONG TOP 40 PRESCRIPTION PHARMACEUTICALS IN 2013 (SALES IN U.S. DOLLARS FOR Q1 2013)</i>	24
<i>TABLE 6 BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS, 2001-2006</i>	26

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 7 EU APPROVED BIOSIMILAR APPLICATIONS, 2012</i>	27
Special Challenges	28
The Biosimilar Market	29
Some Biosimilar Developments and Introductions	30
EPO	30
G-CSF	30
Interferons	30
hGH	30
Monoclonal Antibodies	31
CHAPTER 5 MAJOR GENERIC ISSUES	34
REGULATORY ENVIRONMENT	34
U.S.	34
<i>TABLE 8 REQUIREMENTS FOR NDA AND ANDA APPLICATIONS</i>	35
EUROPEAN UNION	36
EU Marketing Authorization Systems	37
The Centralized Procedure	37
Decentralized and Mutual Recognition Procedures	38
Mutual Recognition Procedure	39
Types of Application	39
Applications under Article 10 (Generic Products)	39
JAPAN	40
Approval (Shonin) of Pharmaceuticals	41
REGULATION OF BIOSIMILARS	41
EU Provisions	41
Evolving Situation in the U.S.	42
User Fees	44
Hatch-Waxman and Bolar	44
DEFENSIVE STRATEGIES BY 'BIG PHARMA'	45
"AUTHORIZED GENERICS"	46
USER FEES	47
A CHANGING CLIMATE FOR GENERICS	48
THE SITUATION IN EUROPE	48
PATENTS AND I.P.	49
SUPPLEMENTARY PROTECTION CERTIFICATES (SPCS)	50
CHAPTER 6 THE GENERIC MARKET	53
GLOBAL PHARMACEUTICAL AND GENERICS MARKET	53
GLOBAL GENERIC MARKET	53
MAIN NATIONAL GENERICS MARKETS	53
<i>TABLE 9 WORLD PHARMA AND GENERIC MARKETS, THROUGH 2018 (\$ BILLIONS)</i>	54
<i>TABLE 10 CURRENT AND FORECAST NATIONAL GENERICS MARKETS, THROUGH 2018 (\$ BILLIONS)</i>	54
MARKET OPPORTUNITIES BY PRODUCT CLASS	55
LEADING GENERIC MOLECULES	55
<i>TABLE 11 TOP 20 GENERIC MOLECULES BY PRESCRIPTION SALES, 2011 (\$ BILLIONS)</i>	55
Anti-infectives	56

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 12 LEADING ANTI-INFECTIVE PRODUCTS RANKED BY SALES IN U.S. DOLLARS FOR Q1 2013.</i>	57
Central Nervous System Therapies	58
Antidepressants	58
Antipsychotics	59
<i>TABLE 13 LEADING CNS PRODUCTS RANKED BY SALES IN Q1 2013</i>	60
Anxiolytics	61
Sleep Disorders	61
Epilepsy	62
Parkinson's Disease	63
Migraine	63
Cardiovascular Products	63
<i>TABLE 14 LEADING CARDIOVASCULAR PRODUCTS BY SALES IN Q1 2013</i>	64
Anti-arthritis Products	65
Steroids	66
NSAIDs	66
COX-II Inhibitors	66
DMARDs	67
<i>TABLE 15 LEADING ANTI-ARTHRITIS PRODUCTS BY SALES IN Q1 2013</i>	67
Respiratory Products	69
Asthma	69
COPD	69
Allergic Rhinitis	69
Bronchodilators	70
Inhaled bronchodilators	70
Anticholinergics	71
Oral bronchodilators	71
Leukotriene antagonists	71
Steroids	71
<i>FIGURE 1 GLOBAL ASTHMA MARKET BY PRODUCT, 2013 (%)</i>	72
<i>TABLE 16 TOP RESPIRATORY DISEASE PRODUCTS RANKED BY SALES IN Q1 2013</i>	73
Anticancer Products	73
Cytotoxic Drugs	73
Hormonal Therapy	74
Biologic Response Modifiers	74
Antiangiogenesis Drugs	74
Monoclonal Antibodies	74
<i>TABLE 17 LEADING ANTICANCER PRODUCTS RANKED BY SALES IN U.S. DOLLARS FOR Q1 2013</i>	75
CHAPTER 7 THE GLOBAL GENERICS INDUSTRY	78
<i>TABLE 18 TOP TEN GENERICS COMPANIES, 2012</i>	78
TRENDS	78
STRUCTURE OF THE GENERICS INDUSTRY	79
RECENT M&A ACTIVITY	80
BRAND COMPANY INVOLVEMENTS	81
CHAPTER 8 PROFILES OF TOP TEN GENERICS COMPANIES	84

<b>TOPIC</b>	<b>PAGE NO.</b>
ACTAVIS	84
APOTEX INC.	85
DR. REDDY'S LABORATORIES LTD.	86
ACQUISITIONS	87
FINANCIALS	88
HOSPIRA, INC.	88
BIOGENERICS	89
FINANCIALS	90
MYLAN INC.	90
FINANCIALS	92
LOOKING AHEAD	92
PAR PHARMACEUTICAL, INC.	92
GENERICS	93
FINANCIALS	94
RANBAXY LABORATORIES LIMITED	94
HISTORY	94
ACQUISITION BY DAIICHI SANKYO	95
FINANCIALS	95
LOOKING AHEAD	96
SANDOZ INTERNATIONAL GMBH	96
PRODUCTS	97
FINANCIALS	98
STADA ARZNEIMITTEL	99
GENERICS	99
BIOSIMILARS	100
FINANCIALS	100
TEVA PHARMACEUTICAL INDUSTRIES LTD	101
FINANCIALS	103
WATSON PHARMACEUTICALS INC.	103
CHAPTER 9 OTHER INTERNATIONAL GENERICS COMPANIES	105
ASPEN PHARMACARE HOLDINGS LTD	105
FINANCIAL RESULTS	106
AUROBINDO PHARMA LTD.	107
PRODUCTS	107
FINANCIALS	108
LOOKING AHEAD	108
BIOCON LTD	108
CIPLA LTD.	110
FINANCIALS	112
COBALT PHARMACEUTICALS	112
EGIS PHARMACEUTICALS PLC	113
APIS	113
PHARMACEUTICAL R&D	114
FINANCIALS	114
GEDEON RICHTER PLC.	115
GENEPHARM GROUP	116

<b>TOPIC</b>	<b>PAGE NO.</b>
KRKA, D. D., NOVO MESTO	117
PRODUCTS	117
FINANCIALS	118
LUPIN LTD	118
FINANCIALS	120
ORION CORPORATION	120
PRODUCTS	120
GENERICS	121
FINANCIALS	121
LOOKING AHEAD	121
PFIZER INC.	121
FINANCIALS	122
PLIVA D.D.	123
ROXANE LABORATORIES INC.	123
SANOFI	124
FINANCIALS	125
LOOKING AHEAD	125
SAWAI PHARMACEUTICAL	125
PRODUCTS	126
FINANCIALS	127
STRIDES ARCOLAB LIMITED	127
PRODUCT RANGE	128
LOOKING AHEAD	129
TANABE SEIYAKU HANBAI	129
WOCKHARDT LIMITED	130
FINANCIALS	131
ZYDUS CADILA	131
FINANCIALS	133
<b>CHAPTER 10 THE AMERICAN REGION</b>	<b>135</b>
UNITED STATES	135
VITAL STATISTICS	135
HEALTH AND HEALTHCARE	135
THE U.S. PHARMACEUTICAL MARKET	136
<i>TABLE 19 U.S. PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2018 (\$ BILLIONS/%)</i>	137
THE GENERIC MARKET: SIZE AND GROWTH	137
Biosimilars	138
Generic Prices	138
"Carve-Outs"	139
Generics Industry	139
<i>FIGURE 2 U.S. PHARMACEUTICAL SHARES BY VALUE (\$ PERCENT) AND PERCENTAGE SHARE OF PRESCRIPTIONS, 2012 (%)</i>	139
The Future	142
CANADA	143
VITAL STATISTICS	143
HEALTH AND HEALTHCARE	143
THE PHARMACEUTICAL MARKET	144

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 20 CANADA PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2018 (\$ BILLIONS/%)</i>	144
GENERICIS	144
Generic Prices	145
<i>TABLE 21 LEADING PHARMA COMPANIES IN CANADA, 2011</i>	146
Future Market Growth	146
How Generics are Supplied	147
LATIN AMERICA	147
BRAZIL	148
Vital Statistics	148
Health and Healthcare	148
Pharmaceutical Market	148
<i>TABLE 22 PHARMACEUTICAL AND GENERICS MARKET IN BRAZIL, THROUGH 2018 (\$ BILLIONS/%)</i>	149
Generic Market	150
M&A Activity	151
Background	151
ProGenericos	153
MEXICO	153
Vital Statistics	153
Health and Healthcare	154
Pharmaceutical Market	154
Generic Sector	155
<i>TABLE 23 PHARMACEUTICAL AND GENERICS MARKET IN MEXICO, THROUGH 2018 (\$ BILLIONS/%)</i>	156
Generic Industry	156
Regulatory Issues	156
AMEGI	158
Recent Developments	159
CHAPTER 11 THE ASIAN REGION	161
JAPAN	161
VITAL STATISTICS	161
HEALTH AND HEALTHCARE	161
PHARMACEUTICAL MARKET	162
<i>TABLE 24 JAPANESE PHARMACEUTICAL AND GENERIC MARKETS, THROUGH 2018 (\$ BILLIONS/%)</i>	162
<i>TABLE 25 TOP FIVE JAPANESE PHARMA COMPANIES, 2012</i>	163
Generic Sector	164
Foreign Presence	165
Market Resistance	166
Generics Industry	166
INDIA	167
VITAL STATISTICS	167
HEALTH AND HEALTHCARE	167
Growing Affluence - Changing Medical Needs	168
Regulatory Changes	168
PHARMACEUTICAL MARKET	168

<b>TOPIC</b>	<b>PAGE NO.</b>
Demographic Factors	168
<i>TABLE 26 INDIAN PHARMACEUTICAL AND GENERIC MARKETS, THROUGH 2018 (\$ BILLIONS/%)</i>	170
Pharma Industry	170
Patent Reform	171
Generic Industry	171
<i>TABLE 27 LEADING PHARMA COMPANIES IN INDIA, 2012</i>	171
CHINA	172
VITAL STATISTICS	173
HEALTH AND HEALTHCARE	173
PHARMACEUTICAL MARKET	174
<i>TABLE 28 PHARMACEUTICAL AND GENERIC MARKET, CHINA, THROUGH 2018 (\$ BILLIONS/%)</i>	175
Domestic Industry	175
Foreign Company Involvement	176
Importance of R&D	177
Challenges	178
Market Trends	178
Regulatory Changes	179
Generic Exports	179
Domestic Generic Market	180
Local Dominance	180
<i>FIGURE 3 GENERIC MARKET THERAPEUTIC CATEGORIES, 2008 (%)</i>	181
CHAPTER 12 THE EUROPEAN REGION	184
FRANCE	184
VITAL STATISTICS	184
HEALTH AND HEALTHCARE	185
Healthcare Provision	185
<i>FIGURE 4 HEALTH EXPENDITURES IN MAJOR EUROPEAN MARKETS AND THE U.S. AS A PERCENTAGE OF GDP, 2007 (%)</i>	185
PHARMACEUTICAL MARKET	186
<i>TABLE 29 PHARMACEUTICAL AND GENERIC MARKET IN FRANCE, THROUGH 2018 (\$ BILLIONS/%)</i>	187
Generic Sector	187
GERMANY	188
VITAL STATISTICS	188
HEALTH AND HEALTHCARE	188
Provision of Healthcare	189
PHARMACEUTICAL MARKET	189
<i>TABLE 30 LEADING THERAPEUTIC CLASSES BY SALES THROUGH STATUTORY HEALTH INSURANCE SCHEME, 2011 (\$ MILLIONS)</i>	190
Price Controls	190
<i>TABLE 31 PHARMACEUTICAL AND GENERIC MARKET IN GERMANY, THROUGH 2018 (\$ BILLIONS)</i>	191
Generics Sector	191
ITALY	192
VITAL STATISTICS	192
HEALTH AND HEALTHCARE	192



<b>TOPIC</b>	<b>PAGE NO.</b>
Healthcare System	193
PHARMACEUTICAL MARKET	193
Implications for Research	195
<i>TABLE 32 SELECTED PRIORITY AREAS IN ITALY'S NATIONAL HEALTH PLAN</i>	195
<i>TABLE 33 PHARMACEUTICAL AND GENERIC MARKET IN ITALY, THROUGH 2018 (\$ BILLIONS/%)</i>	196
Generics Sector	196
SPAIN	197
VITAL STATISTICS	197
HEALTH AND HEALTHCARE	197
Healthcare Provision	198
Pharmaceutical Services	198
PHARMACEUTICAL MARKET	199
<i>TABLE 34 PHARMACEUTICAL AND GENERIC MARKET IN SPAIN, THROUGH 2018 (\$ BILLIONS/%)</i>	200
Generics Sector	200
Generics Industry	200
<i>TABLE 35 LEADING GENERICS COMPANIES IN SPAIN, 2010</i>	201
UNITED KINGDOM	201
VITAL STATISTICS	201
HEALTH AND HEALTHCARE	202
Healthcare Provision	202
Private Sector Involvement	202
Pharmaceuticals	203
THE PHARMACEUTICAL MARKET	203
<i>TABLE 36 LEADING PHARMA COMPANIES IN THE U.K. BY MARKET SHARE, 2011</i>	204
The Generic Sector	205
<i>TABLE 37 PHARMACEUTICAL AND GENERIC MARKET IN UNITED KINGDOM, THROUGH 2018 (\$ BILLIONS/%)</i>	205
RUSSIA	205
VITAL STATISTICS	206
HEALTH AND HEALTHCARE	206
Healthcare Delivery	206
PHARMACEUTICAL MARKET	207
'Pharma 2020'	207
<i>TABLE 38 PHARMACEUTICAL AND GENERIC MARKET IN RUSSIA, THROUGH 2018 (\$ BILLIONS/%)</i>	208
<i>TABLE 39 LEADING PHARMA COMPANIES IN RUSSIA, BY SALES, 2012</i>	208
Generics Sector	209

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE MAJOR NATIONAL GENERIC MARKETS, THROUGH 2018 (\$ BILLIONS)	8
TABLE 1 GLOBAL PHARMACEUTICAL AND GENERICS MARKETS BY REGION, THROUGH 2018 (\$ BILLIONS)	11
TABLE 2 MAJOR PATENT EXPIRATIONS IN 2011 AND 2012	18
TABLE 3 MAJOR PATENT EXPIRIES IN 2013 WITH PEAK BRAND SALES BEFORE EXPIRIES	18
TABLE 4 BRAND SALES BEFORE AND AFTER PATENT EXPIRY (\$ BILLIONS)	19
TABLE 5 BIOTHERAPEUTICS AMONG TOP 40 PRESCRIPTION PHARMACEUTICALS IN 2013 (SALES IN U.S. DOLLARS FOR Q1 2013)	24
TABLE 6 BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS, 2001-2006	26
TABLE 7 EU APPROVED BIOSIMILAR APPLICATIONS, 2012	27
TABLE 8 REQUIREMENTS FOR NDA AND ANDA APPLICATIONS	35
TABLE 9 WORLD PHARMA AND GENERIC MARKETS, THROUGH 2018 (\$ BILLIONS)	54
TABLE 10 CURRENT AND FORECAST NATIONAL GENERICS MARKETS, THROUGH 2018 (\$ BILLIONS)	54
TABLE 11 TOP 20 GENERIC MOLECULES BY PRESCRIPTION SALES, 2011 (\$ BILLIONS)	55
TABLE 12 LEADING ANTI-INFECTIVE PRODUCTS RANKED BY SALES IN U.S. DOLLARS FOR Q1 2013.	57
TABLE 13 LEADING CNS PRODUCTS RANKED BY SALES IN Q1 2013	60
TABLE 14 LEADING CARDIOVASCULAR PRODUCTS BY SALES IN Q1 2013	64
TABLE 15 LEADING ANTI-ARTHRITIS PRODUCTS BY SALES IN Q1 2013	67
TABLE 16 TOP RESPIRATORY DISEASE PRODUCTS RANKED BY SALES IN Q1 2013	73
TABLE 17 LEADING ANTICANCER PRODUCTS RANKED BY SALES IN U.S. DOLLARS FOR Q1 2013	75
TABLE 18 TOP TEN GENERICS COMPANIES, 2012	78
TABLE 19 U.S. PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2018 (\$ BILLIONS/%)	137
TABLE 20 CANADA PHARMACEUTICAL AND GENERICS MARKETS, THROUGH 2018 (\$ BILLIONS/%)	144
TABLE 21 LEADING PHARMA COMPANIES IN CANADA, 2011	146
TABLE 22 PHARMACEUTICAL AND GENERICS MARKET IN BRAZIL, THROUGH 2018 (\$ BILLIONS/%)	149
TABLE 23 PHARMACEUTICAL AND GENERICS MARKET IN MEXICO, THROUGH 2018 (\$ BILLIONS/%)	156
TABLE 24 JAPANESE PHARMACEUTICAL AND GENERIC MARKETS, THROUGH 2018 (\$ BILLIONS/%)	162
TABLE 25 TOP FIVE JAPANESE PHARMA COMPANIES, 2012	163
TABLE 26 INDIAN PHARMACEUTICAL AND GENERIC MARKETS, THROUGH 2018 (\$ BILLIONS/%)	170
TABLE 27 LEADING PHARMA COMPANIES IN INDIA, 2012	171
TABLE 28 PHARMACEUTICAL AND GENERIC MARKET, CHINA, THROUGH 2018 (\$ BILLIONS/%)	175
TABLE 29 PHARMACEUTICAL AND GENERIC MARKET IN FRANCE, THROUGH 2018 (\$ BILLIONS/%)	187
TABLE 30 LEADING THERAPEUTIC CLASSES BY SALES THROUGH STATUTORY HEALTH INSURANCE SCHEME, 2011 (\$ MILLIONS)	190
TABLE 31 PHARMACEUTICAL AND GENERIC MARKET IN GERMANY, THROUGH 2018 (\$ BILLIONS)	191
TABLE 32 SELECTED PRIORITY AREAS IN ITALY'S NATIONAL HEALTH PLAN	195

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 33 PHARMACEUTICAL AND GENERIC MARKET IN ITALY, THROUGH 2018 (\$ BILLIONS/%)	196
TABLE 34 PHARMACEUTICAL AND GENERIC MARKET IN SPAIN, THROUGH 2018 (\$ BILLIONS/%)	200
TABLE 35 LEADING GENERICS COMPANIES IN SPAIN, 2010	201
TABLE 36 LEADING PHARMA COMPANIES IN THE U.K. BY MARKET SHARE, 2011	204
TABLE 37 PHARMACEUTICAL AND GENERIC MARKET IN UNITED KINGDOM, THROUGH 2018 (\$ BILLIONS/%)	205
TABLE 38 PHARMACEUTICAL AND GENERIC MARKET IN RUSSIA, THROUGH 2018 (\$ BILLIONS/%)	208
TABLE 39 LEADING PHARMA COMPANIES IN RUSSIA, BY SALES, 2012	208

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE MAJOR NATIONAL GENERIC MARKETS, 2012-2018 (\$ BILLIONS)	8
FIGURE 1 GLOBAL ASTHMA MARKET BY PRODUCT, 2013 (%)	72
FIGURE 2 U.S. PHARMACEUTICAL SHARES BY VALUE (\$ PERCENT) AND PERCENTAGE SHARE OF PRESCRIPTIONS, 2012 (%)	139
FIGURE 3 GENERIC MARKET THERAPEUTIC CATEGORIES, 2008 (%)	181
FIGURE 4 HEALTH EXPENDITURES IN MAJOR EUROPEAN MARKETS AND THE U.S. AS A PERCENTAGE OF GDP, 2007 (%)	185